In the original published version of this article the formatting of [Table 4](#sfw141-T4){ref-type="table"} was partially incorrect. This error has now been corrected in the final published version of the article and the correct version of [Table 4](#sfw141-T4){ref-type="table"} is also given below: Table 4.Treatment quality (mean values), comedication^a^ and QoL parameters (maximum likelihood estimates)MonthAge \<75 yearsAge ≥75 years eKt/V^b^01.321.29121.371.33241.461.40Change from BL^c^**P \< 0.01P \< 0.01** Haemoglobin (g/dL)011.611.81211.911.82411.811.8Change from BL**P\<0.01**P = 0.94 Corrected total calcium (mmol/L)02.302.31122.282.30242.262.28Change from BL**P\<0.01P\<0.01** Phosphate (mmol/L)01.901.72121.861.72241.811.72Change from BL**P\<0.01**P = 1.00 Corrected calcium × phosphate product (mmol^2^/L^2^)04.414.02124.233.98244.133.93Change from BL**P\<0.01**P = 0.12 iPTH (pmol/L)014.713.31216.114.22417.117.1Change from BL**P\<0.01P\<0.01** Albumin (g/L)040.138.71240.539.12440.638.9Change from BL**P\<0.01**P = 0.50 HbA1c (%)06.166.07126.095.94246.035.96Change from BL**P\<0.01P\<0.05** Transferrin saturation (%)023.923.81225.724.52424.724.4Change from BL**P\<0.05**P = 0.36 Ferritin (µg/L)03403541247648524501508Change from BL**P\<0.01P\<0.01** CRP (mg/L)06.126.82125.956.49246.026.79Change from BLP = 0.66P = 0.96 BMI (kg/m^2^)026.425.61226.325.22426.125.0Change from BL**P\<0.01P\<0.01** Weekly darbepoetin alfa dose (µg/week)035.334.01232.131.52432.030.6 Antihypertensive agents (excluding diuretics)087.3%84.4%1284.6%82.7%2483.6%81.6% Diuretics069.3%74.0%1263.1%68.8%2459.0%63.7% Cardiac glycosides08.6%14.1%129.3%13.2%2410.6%13.5% Iron therapy077.0%79.3%1269.2%70.9%2469.5%70.8% Phosphate binders081.9%69.1%1282.0%73.3%2482.4%73.6% Vitamin D062.6%60.1%1262.6%63.7%2463.5%69.5% Physical well-being (PWB) (score range 0--28)020.418.71220.218.22419.617.3Change from BL−3.9%−7.5%**P\<0.01P\<0.01** Social well-being (SWB) (score range 0--28)021.020.81220.820.52420.420.4Change from BL−2.9%−1.9%**P\<0.01**P = 0.37 Emotional well-being (EWB) (score range 0--24)017.116.41217.216.22416.915.8Change from BL−1.2%−3.7%P = 0.23P = 0.11 Functional well-being (FWB) (score range 0--28)016.014.51215.914.02415.412.6Change from BL−3.8%−13.1%**P\<0.01P\<0.01** FACT-G (score range 0--108)074.470.3 (PWB + SWB + EWB + FWB)1273.968.72472.065.9Change from BL−3.2%−6.3%**P\<0.01P\<0.01** Anaemia subscale (AnS) (score range 0--80)035.530.91235.030.52434.329.3Change from BL−3.4%−5.2%**P\<0.01P\<0.05** Trial Outcome Index (TOI) (score range 0--136)071.963.9 (PWB + FWB + AnS)1271.062.52469.359.1Change from BL−3.6%−7.5%**P\<0.01P\<0.01** FACT-An (score range 0--188)0109.9101.1 (FACT-G + AnS)12108.999.224106.395.2Change from BL−3.6%−5.8%**P\<0.01P\<0.01**[^1][^2][^3]

The publisher apologizes for this error.

[^1]: ^a^Assuming proportionally distributed events in missing cases when calculating percentages.

[^2]: ^b^Equilibrated Kt/V was computed according to the double pool Daugirdas equation for arteriovenous and venovenous accesses. Blood samples were taken according to the European Best Practice Guidelines for Haemodialysis after a long interval of the respective dialysis regimen \[9, 10\].

[^3]: ^c^Relative mean change from baseline (BL) to month 24 (negative values denote a decrease).
